Edward B. Garon
University of California, Los Angeles
3 papers in the Anchorcite directory, published between 2015 and 2018, cited 20,966 times in total.
ORCID profileResearch topics
- Cancer Immunotherapy and Biomarkers · 3 papers
- Lung Cancer Treatments and Mutations · 3 papers
- Cancer Genomics and Diagnostics · 1 paper
- Lung Cancer Diagnosis and Treatment · 1 paper
- Lung Cancer Research Studies · 1 paper
Frequent co-authors
- Naiyer A. Rizvi · 2 papers
- Matthew David Hellmann · 2 papers
- Leena Gandhi · 2 papers
- Enriqueta Felip · 2 papers
- Rina Hui · 2 papers
- Alexandra Snyder · 1 paper
- Pia Kvistborg · 1 paper
- Vladimir Makarov · 1 paper
Papers
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience · 2015 · 7,918 citations
Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are revolutionizing cancer treatment. To unravel the genomic determinants of response to this therapy, we used whole-exome sequencing of non-small cell lung cancers treated with pembrolizumab, an…
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine · 2018 · 6,754 citations
BACKGROUND: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the…
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 6,294 citations
BACKGROUND: We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression level of…
Metadata from OpenAlex (CC0).